Brief: Vivos Therapeutics Closes Acquisition Of Stake In Sod Sciences And 50% Interest In Pseudohypoxia Test, Opening A Potential Path To Access More Than 325,000 New Patients Through The Aha Channel
Mon 23:10
BRIEF-Vivos Therapeutics Closes Acquisition Of Stake In Sod Sciences And 50% Interest In Pseudohypoxia Test, Opening A Potential Path To Access More Than 325,000 New Patients Through The Aha Channel Oct 19 (Reuters) - Vivos Therapeutics Inc VVOS.O:
VIVOS THERAPEUTICS CLOSES ACQUISITION OF STAKE IN SOD SCIENCES AND 50% INTEREST IN PSEUDOHYPOXIA TEST, OPENING A POTENTIAL PATH TO ACCESS MORE THAN 325,000 NEW PATIENTS THROUGH THE AHA CHANNEL
Source text: ID:nGNX1t8l05
Further company coverage: VVOS.O
((((Reuters.Briefs@thomsonreuters.com;));))
Recent news on Vivos Therapeutics
See all newsBrief: Vivos Therapeutics Closes Acquisition Of Stake In Sod Sciences And 50% Interest In Pseudohypoxia Test, Opening A Potential Path To Access More Than 325,000 New Patients Through The Aha Channel
Brief: Vivos Therapeutics - Audit Reports For Fy2025 And Fy2024 Include Substantial Doubt About Going Concern
Brief: Vivos Therapeutics And South Palm Cardiovascular Associates Sign Definitive Agreements To Launch Regional Sleep Testing And Treatment Center
Vivos Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Vivos Therapeutics Q2 revenue rises 35% on service growth